HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Money

Earnings analysis, pricing strategy, and financial dynamics

Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitors
MoneyFierceBiotech ↗
Terremoto Biosciences has spelt out how the California biotech will use a $108 million series C round to conti…
Apr 17, 2026
Spain sets up Boston-focused VC fund with goal of raising $200M for biotechs
MoneyFierceBiotech ↗
The Spanish government has announced a goal to raise a $200 million venture capital fund to launch the Spain-B…
Apr 17, 2026
Bain-backed Beeline Medicines buzzes out of stealth with $300M and 5 programs from BMS
MoneyFierceBiotech ↗
The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing fro…
Apr 17, 2026
J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde
MoneyFiercePharma ↗
Protagonist Therapeutics-partnered Icotyde has the potential to become one of Johnson & Johnson's "largest…
Apr 17, 2026
Storm’s $56M Raise Puts RNA Editing on Venture Capital’s Radar
Money
Backed by Pfizer Ventures and M Ventures, Storm Therapeutics’ $56M Series C funds a Phase 2 sarcoma trial and …
Apr 17, 2026
Kailera’s $625M IPO Reopens the Biotech Window
MoneyBriefing
The Waltham-based obesity biotech priced at the top of its range, surpassing Moderna’s 2018 record and signali…
Apr 17, 2026
← Newer Page 6 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.